Clinical, economic, and societal burden of cystic fibrosis and the impact of the CFTR modulator, lumacaftor/ivacaftor: an assessment using linked registry data in Sweden

Anders Lindblada Department of Paediatrics, Institute of Clinical Science at The Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg, SwedenCorrespondence[email protected]

Isabelle de Monestrolb Stockholm Cystic Fibrosis Centre, Karolinska University Hospital, Karolinska Institutet, Huddinge, Sweden

Marita Gilljamc Gothenburg CF center, Vita Stråket 12, Sahlgrenska University Hospital, Gothenburg, Sweden

Christina Krantzd Uppsala Centre for Cystic Fibrosis, Uppsala University Hospital, Uppsala, Sweden

Lisa J. McGarrye Vertex Pharmaceuticals Incorporated, Boston, MA, USA

Jonas Banefeltf Quantify Research, Stockholm, Sweden

Martina Aldvénf Quantify Research, Stockholm, Sweden

show all

Clinical, economic, and societal burden of cystic fibrosis and the impact of the CFTR modulator, lumacaftor/ivacaftor: an assessment using linked registry data in Sweden

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Clinical, economic, and societal burden of cystic fibrosis and the impact of the CFTR modulator, lumacaftor/ivacaftor: an assessment using linked registry data in Sweden

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date